Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Depreciation & Amortization - Total: 2022-2024

Historic Depreciation & Amortization - Total for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $130,977.

  • Addex Therapeutics' Depreciation & Amortization - Total fell 51.33% to $130,977 in Q4 2024 from the same period last year, while for Dec 2024 it was -$105,647, marking a year-over-year decrease of 928.15%. This contributed to the annual value of -$207,275 for FY2024, which is 1684.05% down from last year.
  • Latest data reveals that Addex Therapeutics reported Depreciation & Amortization - Total of $130,977 as of Q4 2024, which was up 257.60% from -$83,105 recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Depreciation & Amortization - Total registered a high of $477,876 during Q4 2022, and its lowest value of -$234,797 during Q3 2023.
  • In the last 3 years, Addex Therapeutics' Depreciation & Amortization - Total had a median value of -$76,760 in 2024 and averaged -$7,219.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first soared by 91.29% in 2023, then crashed by 963.71% in 2024.
  • Over the past 3 years, Addex Therapeutics' Depreciation & Amortization - Total (Quarterly) stood at $477,876 in 2022, then crashed by 43.68% to $269,119 in 2023, then tumbled by 51.33% to $130,977 in 2024.
  • Its Depreciation & Amortization - Total was $130,977 in Q4 2024, compared to -$83,105 in Q3 2024 and -$77,053 in Q2 2024.